These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30258212)

  • 41. Analysis of the evolution of cortical and trabecular bone compartments in the proximal femur after spinal cord injury by 3D-DXA.
    Gifre L; Humbert L; Muxi A; Del Rio L; Vidal J; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2018 Jan; 29(1):201-209. PubMed ID: 29043391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.
    Vegger JB; Brüel A; Thomsen JS
    J Musculoskelet Neuronal Interact; 2018 Jun; 18(2):165-175. PubMed ID: 29855438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study.
    Gilchrist NL; Frampton CM; Acland RH; Nicholls MG; March RL; Maguire P; Heard A; Reilly P; Marshall K
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1385-90. PubMed ID: 17227802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R; Gesztesi Z; Rochford J
    Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between
    Cirnigliaro CM; Parrott JS; Myslinski MJ; Asselin P; Lombard AT; La Fountaine MF; Kirshblum SC; Forrest GF; Dyson-Hudson T; Spungen AM; Bauman WA
    J Spinal Cord Med; 2020 Sep; 43(5):685-695. PubMed ID: 31663832
    [No Abstract]   [Full Text] [Related]  

  • 47. Inverse Correlation at the Hip Between Areal Bone Mineral Density Measured by Dual-Energy X-ray Absorptiometry and Cortical Volumetric Bone Mineral Density Measured by Quantitative Computed Tomography.
    Amstrup AK; Jakobsen NF; Lomholt S; Sikjaer T; Mosekilde L; Rejnmark L
    J Clin Densitom; 2016; 19(2):226-33. PubMed ID: 25700661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of cycling and/or electrical stimulation on bone mineral density in children with spinal cord injury.
    Lauer RT; Smith BT; Mulcahey MJ; Betz RR; Johnston TE
    Spinal Cord; 2011 Aug; 49(8):917-23. PubMed ID: 21423253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relationship between basal metabolic rate and femur bone mineral density in men with traumatic spinal cord injury.
    Yilmaz B; Yasar E; Goktepe AS; Onder ME; Alaca R; Yazicioglu K; Mohur H
    Arch Phys Med Rehabil; 2007 Jun; 88(6):758-61. PubMed ID: 17532898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of a vitamin D analog on leg bone mineral density in patients with chronic spinal cord injury.
    Bauman WA; Spungen AM; Morrison N; Zhang RL; Schwartz E
    J Rehabil Res Dev; 2005; 42(5):625-34. PubMed ID: 16586188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
    Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
    Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a simplified hip structure analysis method for the prediction of incident hip fracture events.
    Khoo BC; Lewis JR; Brown K; Prince RL
    Osteoporos Int; 2016 Jan; 27(1):241-8. PubMed ID: 26282230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review.
    Soleyman-Jahi S; Yousefian A; Maheronnaghsh R; Shokraneh F; Zadegan SA; Soltani A; Hosseini SM; Vaccaro AR; Rahimi-Movaghar V
    Eur Spine J; 2018 Aug; 27(8):1798-1814. PubMed ID: 28497215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of postoperative osteopenia using IV pamidronate: a pilot study.
    Hobby BD; Dominguez-Bartmess S; Szalay EA
    J Pediatr Orthop; 2013; 33(7):763-7. PubMed ID: 23872799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correspondence: "Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial".
    Beaupre GS
    Spinal Cord; 2018 Dec; 56(12):1212. PubMed ID: 30467328
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study.
    Dabbaghmanesh A; Bakhshayeshkaram M; Roshanzamir S; Naseri A; Dabbaghmanesh MM; Heydari ST; Talehzadeh P; Dabbaghmanesh MH; Jahromi SE
    BMC Nephrol; 2023 Nov; 24(1):331. PubMed ID: 37940839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics Associated with Bone Loss after Spinal Cord Injury: Implications for Hip Region Vulnerability.
    Han S; Shin S; Kim O; Hong N
    Endocrinol Metab (Seoul); 2023 Oct; 38(5):578-587. PubMed ID: 37816499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.